|
| Tuesday, July 26, 2022 |
|
|
全球创新药加速发展 知临集团SACT-1已获FDA孤儿药资格认证 |
人口老龄化加速、医药创新技术不断更新，全球创新药发展持续加速，未来医药市场有望保持增长趋势。根据弗若斯特沙利文预测，到 2025 年全球医药市场规模预计达到 17114 亿美元。
more info >> |
|
|
全球創新藥加速發展 知臨集團SACT-1已獲FDA孤兒藥資格認證 |
| 人口老齡化加速、醫藥創新技術不斷更新，全球創新藥發展持續加速，未來醫藥市場有望保持增長趨勢。根據弗若斯特沙利文預測，到 2025 年全球醫藥市場規模預計達到 17114 億美元。 more info >> |
|
|
The Global Pharmaceutical Industry is Accelerating; Aptorum Group Has Received Orphan Drug Designation from US FDA for Its SACT-1 |
| The aging of the population is accelerating, pharmaceutical technology is constantly updating, and the development of the global pharmaceutical industry continues to accelerate. The pharmaceutical market is expected to maintain a growing trend. According to Frost & Sullivan, the global pharmaceutical market is expected to reach $1,711.4 billion by 2025. more info >> |
|
| Tuesday, September 29, 2020 |
|
|
知臨集團開設傳染病液體活檢初創子公司，獨家獲得了新加坡Accelerate Technologies的許可以共同開發基於基因組分析以追蹤病原體基因組的快速分子病原體診斷技術 |
| 致力於開發創新科技包括傳染性疾病療法的生物製藥公司知臨集團（納斯達克：APM；巴黎泛歐證券交易所：APM）（「知臨集團」或者「知臨」），宣布建立傳染病液體生物檢測子公司—— Aptorum Innovations並通過最近與新加坡科技研究局（「A*STAR」） more info >> |
|
|
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary, Announces Exclusive In-license from Singapore-based Accelerate Technologies to Co-Develop Molecular Based Rapid Pathogen Diagnostics to Track Pathogenic Genome |
| Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced its launch of Aptorum Innovations more info >> |
|
| Tuesday, September 8, 2020 |
|
|
Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10 |
| Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel therapeutics including the development of next-generation approach therapeutics targeting antimicrobial resistance, today announced President and Executive Director more info >> |
|
|
Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance |
| Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group"), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the "BEAM Alliance") as full member. more info >> |
|
| Tuesday, September 1, 2020 |
|
|
Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models |
| Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group"), a biopharmaceutical company focused on novel therapeutics including the development of next-generation approach therapeutics targeting antimicrobial resistance more info >> |
|
|
Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types |
| Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics including orphan diseases and oncology indications more info >> |
|
|
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020 |
| Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group"or the "Company"), a biopharmaceutical company focuses on the development of novel therapeutics to address global unmet medical needs, today provided a business update and announced financial results for the six months ended June 30, 2020. more info >> |
|
|
|
|
